Epigral has received approval to raise funds up to Rs 400 crore by way of issuance of non-convertible debentures (NCDs), bonds and/or other debt securities etc. through permissible mode within the borrowing limits of the company, in one or more tranches / series. The board of directors of the company in their meeting held on August 2, 2025, have approved the same.
Epigral is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives. The Company is also engaged in Trading of Agrochemical products.
| Company Name | CMP |
|---|---|
| BASF India | 4035.90 |
| Tata Chemicals | 782.10 |
| SRF | 2780.75 |
| Pidilite Inds. | 1476.15 |
| Deepak Nitrite | 1875.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: